Niels Frimodt-MÃ¸ller

List of Publications by Year
in descending order

299 papers	11,766 citations	26630 56 h-index	43889 91 g-index
309 all docs	309 docs citations	309 times ranked	12292 citing authors

#	Article	IF	Citations
1	The importance of understanding the infectious microenvironment. Lancet Infectious Diseases, The, 2022, 22, e88-e92.	9.1	78
2	Reservoir of Antibiotic Residues and Resistant Coagulase Negative Staphylococci in a Healthy Population in the Greater Accra Region, Ghana. Antibiotics, 2022, 11, 119.	3.7	3
3	Novel risk factors associated with common vaginal infections: a nationwide primary health care cohort study. International Journal of Infectious Diseases, 2022, 116, 380-386.	3.3	5
4	Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model. International Journal of Antimicrobial Agents, 2022, 59, 106543.	2.5	4
5	One Day in Denmark: Nationwide point-prevalence survey of human bacterial isolates and comparison of classical and whole-genome sequence-based species identification methods. PLoS ONE, 2022, 17, e0261999.	2.5	5
6	Socioeconomic functioning in patients with brain abscess â€“ a nationwide, population-based cohort study in Denmark. Journal of Infection, 2022, 84, 621-627.	3.3	3
7	Dentistâ€™s Visits and Risk of Brain Abscess: A Nationwide, Population-Based Case-Control Study. Clinical Infectious Diseases, 2022, 75, 824-829.	5.8	9
8	The association between common urogenital infections and cervical neoplasia â€“ A nationwide cohort study of over four million women (2002â€“2018). Lancet Regional Health - Europe, The, 2022, 17, 100378.	5.6	1
9	Increased shortâ€•and longâ€•term mortality following infections in dementia: a nationwide registryâ€•based cohort study. European Journal of Neurology, 2021, 28, 411-420.	3.3	5
10	Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening. Journal of Antimicrobial Chemotherapy, 2021, 76, 1001-1009.	3.0	22
11	Asymptomatic Bacteriuria (ABU) in Elderly: Prevalence, Virulence, Phylogeny, Antibiotic Resistance and Complement C3 in Urine. Microorganisms, 2021, 9, 390.	3.6	7
12	Dementia identified as a risk factor for infection-related hospital contacts in a national, population-based and longitudinal matched-cohort study. Nature Aging, 2021, 1, 226-233.	11.6	6
13	Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study. Clinical Infectious Diseases, 2021, 73, 866-872.	5.8	12
14	Betaâ€•hemolytic streptococci A, C, and G are susceptible to cloxacillin. Apmis, 2021, 129, 314-316.	2.0	1
15	Aminoglycoside resistance genes in Enterococcus faecium: mismatch with phenotype. Journal of Antimicrobial Chemotherapy, 2021, 76, 2215-2217.	3.0	4
16	Hospital readmissions following infections in dementia: a nationwide and registryâ€•based cohort study. European Journal of Neurology, 2021, 28, 3603-3614.	3.3	0
17	Escherichia coli Causing Recurrent Urinary Tract Infections: Comparison to Non-Recurrent Isolates and Genomic Adaptation in Recurrent Infections. Microorganisms, 2021, 9, 1416.	3.6	14
18	Danish Whole-Genome-Sequenced Candida albicans and Candida glabrata Samples Fit into Globally Prevalent Clades. Journal of Fungi (Basel, Switzerland), 2021, 7, 962.	3.5	3

#	Article	IF	Citations
19	In vitro Relative Fitness, in vivo Intestinal Colonization and Genomic Differences of Escherichia coli of ST131 Carrying blaCTXâ€“Mâ€“15. Frontiers in Microbiology, 2021, 12, 798473.	3.5	4
20	Hospital readmissions following infections in dementia: A nationwide and registryâ€based cohort study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
21	Microbiome Compositions and Resistome Levels after Antibiotic Treatment of Critically Ill Patients: An Observational Cohort Study. Microorganisms, 2021, 9, 2542.	3.6	4
22	A clear conscience is the sure sign of a bad memory: vancomycin-resistant enterococci and rectal thermometers. Journal of Hospital Infection, 2020, 105, 108-109.	2.9	1
23	Oral amoxicillin and amoxicillinâ€“clavulanic acid: properties, indications and usage. Clinical Microbiology and Infection, 2020, 26, 871-879.	6.0	106
24	Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model. International Journal of Antimicrobial Agents, 2020, 55, 105851.	2.5	10
25	Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	5
26	Horizontally acquired papGII-containing pathogenicity islands underlie the emergence of invasive uropathogenic Escherichia coli lineages. Nature Communications, 2020, 11, 5968.	12.8	42
27	Increased excess shortâ€and longâ€term mortality following infections in dementia: A prospective nationwide and registryâ€based cohort study. Alzheimer's and Dementia, 2020, 16, e038941.	0.8	2
28	Exposure of consumers to substandard antibiotics from selected authorised and unauthorised medicine sales outlets in Ghana. Tropical Medicine and International Health, 2020, 25, 962-975.	2.3	17
29	Counting Replication Origins to Measure Growth of Pathogens. Antibiotics, 2020, 9, 239.	3.7	0
30	Retrospective study of men with E. coli UTI treated with an oral antibiotic, and risk for a new prescription or hospital admission due to UTI. Scandinavian Journal of Primary Health Care, 2020, 38, 101-103.	1.5	0
31	A snapshot of diversity: Intraclonal variation of Escherichia coli clones as commensals and pathogens. International Journal of Medical Microbiology, 2020, 310, 151401.	3.6	7
32	Effects of Antibiotics on the Intestinal Microbiota of Mice. Antibiotics, 2020, 9, 191.	3.7	22
33	Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. Journal of Medical Microbiology, 2020, 69, 387-395.	1.8	5
34	Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa. Journal of Pediatric Hematology/Oncology, 2020, 42, e783-e787.	0.6	2
35	Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not â€“ a retrospective cohort study . Infection and Drug Resistance, 2019, Volume 12, 1691-1702.	2.7	14
36	Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine, 2019, 12, 62-69.	7.1	10

#	Article	IF	Citations
37	Growth Rate of Escherichia coli During Human Urinary Tract Infection: Implications for Antibiotic Effect. Antibiotics, 2019, 8, 92.	3.7	5
38	Mutational change of CTXâ€Mâ€15 to CTXâ€Mâ€127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. MicrobiologyOpen, 2019, 8, e941.	3.0	9
39	Community-acquired meningitis caused by beta-haemolytic streptococci in adults: a nationwide population-based cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2305-2310.	2.9	6
40	Escherichia coli belonging to ST131 rarely transfers bla_{ctx-m-15} to fecal Escherichia coli . Infection and Drug Resistance, 2019, Volume 12, 2429-2435.	2.7	5
41	Involvement of NLRP3 and NLRC4 Inflammasome in Uropathogenic E. coli Mediated Urinary Tract Infections. Frontiers in Microbiology, 2019, 10, 2020.	3.5	24
42	The urine microbiome â€“ Contamination or a novel paradigm?. EBioMedicine, 2019, 44, 20-21.	6.1	6
43	Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2767-2773.	3.0	10
44	Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial. Trials, 2019, 20, 250.	1.6	18
45	Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticusâ€"Cumulative Observational Data from Four Recent Clinical Studies. Antibiotics, 2019, 8, 57.	3.7	7
46	Nosocomial urinary tract infection and risk of bacteraemia in elderly patients: urinary catheter, clinical factors and bacterial species. Infectious Diseases, 2019, 51, 547-549.	2.8	6
47	Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review. Acta Anaesthesiologica Scandinavica, 2019, 63, 973-978.	1.6	3
48	LRE-Finder, a Web tool for detection of the 23S rRNA mutations and the optrA, cfr, cfr(B) and poxtA genes encoding linezolid resistance in enterococci from whole-genome sequences. Journal of Antimicrobial Chemotherapy, 2019, 74, 1473-1476.	3.0	58
49	Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz086.	0.9	17
50	Comparison of methods for measuring antibiotic consumption in an intensive care unit. Apmis, 2019, 127, 33-40.	2.0	4
51	Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
52	Selection of ESBL-Producing E. coli in a Mouse Intestinal Colonization Model. Methods in Molecular Biology, 2018, 1736, 105-115.	0.9	2
53	Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-Î²-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
54	Chromosome replication as a measure of bacterial growth rate during Escherichia coli infection in the mouse peritonitis model. Scientific Reports, 2018, 8, 14961.	3.3	34

#	Article	IF	Citations
55	Use of diagnostic tests and the appropriateness of the treatment decision in patients with suspected urinary tract infection in primary care in Denmark â€“ observational study. BMC Family Practice, 2018, 19, 65.	2.9	16
56	Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review. Infection and Drug Resistance, 2018, Volume 11, 761-771.	2.7	23
57	Detection of the optrA gene in a clinical ST16 Enterococcus faecalis isolate in Denmark. Journal of Global Antimicrobial Resistance, 2017, 10, 12-13.	2.2	19
58	Clinical accuracy of point-of-care urine culture in general practice. Scandinavian Journal of Primary Health Care, 2017, 35, 170-177.	1.5	12
59	Whole-genome comparison of urinary pathogenic Escherichia coli and faecal isolates of UTI patients and healthy controls. International Journal of Medical Microbiology, 2017, 307, 497-507.	3.6	57
60	Mecillinam â€“ Reversion of Resistance and How to Test It. EBioMedicine, 2017, 23, 4-5.	6.1	4
61	Effect of point-of-care susceptibility testing in general practice on appropriate prescription of antibiotics for patients with uncomplicated urinary tract infection: a diagnostic randomised controlled trial. BMJ Open, 2017, 7, e018028.	1.9	16
62	Comparison of two commercial broad-range PCR and sequencing assays for identification of bacteria in culture-negative clinical samples. BMC Infectious Diseases, 2017, 17, 233.	2.9	19
63	Carriage and serotype distribution of Streptococcus agalactiae in third trimester pregnancy in southern Ghana. BMC Pregnancy and Childbirth, 2017, 17, 238.	2.4	21
64	Situational analysis of antibiotic use and resistance in Ghana: policy and regulation. BMC Public Health, 2017, 17, 896.	2.9	74
65	Temocillinin vitroactivity against recent clinical isolates ofNeisseria gonorrhoeaecompared with penicillin, ceftriaxone and ciprofloxacin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1122-1123.	3.0	3
66	â€œPopulation structure of Drug-Susceptible, -Resistant and ESBL-producing Escherichia coli from Community-Acquired Urinary Tract Infectionsâ€• BMC Microbiology, 2016, 16, 63.	3.3	55
67	Automated surveillance system for hospital-acquired urinary tract infections in Denmark. Journal of Hospital Infection, 2016, 93, 290-296.	2.9	9
68	Uropathogenic Escherichia coli Metabolite-Dependent Quiescence and Persistence May Explain Antibiotic Tolerance during Urinary Tract Infection. MSphere, 2016, 1, .	2.9	37
69	Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry. Apmis, 2016, 124, 1004-1015.	2.0	21
70	Adaptation of Escherichia coli traversing from the faecal environment to the urinary tract. International Journal of Medical Microbiology, 2016, 306, 595-603.	3.6	16
71	The efficacy of pivmecillinam: 3Âdays or 5Âdaysâ€‰t.i.d against community acquired uncomplicated lower urinary tract infections â€“ a randomized, double-blinded, placebo-controlled clinical trial study protocol. BMC Infectious Diseases, 2016, 16, 727.	2.9	6
72	Comparative Evaluation of Inoculation of Urine Samples with the Copan WASP and BD Kiestra InoqulA Instruments. Journal of Clinical Microbiology, 2016, 54, 328-332.	3.9	30

#	Article	IF	Citations
73	Epidemiological factors associated with ESBL- and non ESBL-producingE. colicausing urinary tract infection in general practice. Infectious Diseases, 2016, 48, 241-245.	2.8	33
74	An Amphipathic Undecapeptide with All <scp>d</scp> -Amino Acids Shows Promising Activity against Colistin-Resistant Strains of Acinetobacter baumannii and a Dual Mode of Action. Antimicrobial Agents and Chemotherapy, 2016, 60, 592-599.	3.2	34
75	Effects of a Mutation in the gyrA Gene on the Virulence of Uropathogenic Escherichia coli. Antimicrobial Agents and Chemotherapy, 2015, 59, 4662-4668.	3.2	14
76	Multidrug-Resistant Streptococcus pneumoniae Isolates from Healthy Ghanaian Preschool Children. Microbial Drug Resistance, 2015, 21, 636-642.	2.0	12
77	Rational Design of Alphaâ€Helical Antimicrobial Peptides: Do's and Don'ts. ChemBioChem, 2015, 16, 242-253.	2.6	67
78	Clonal distribution of pneumococcal serotype 19F isolates from Ghana. Infection, Genetics and Evolution, 2015, 31, 68-72.	2.3	2
79	End group modification: Efficient tool for improving activity of antimicrobial peptide analogues towards Gram-positive bacteria. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 40-46.	4.3	23
80	Commensal Streptococci Serve as a Reservoir for Î²-Lactam Resistance Genes in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 3529-3540.	3.2	74
81	Limited similarity between plasmids encoding CTX-M-1 Î²-lactamase in Escherichia coli from humans, pigs, cattle, organic poultry layers and horses in Denmark. Journal of Global Antimicrobial Resistance, 2015, 3, 132-136.	2.2	26
82	The effect of glycine replacement with flexible Ï‰-amino acids on the antimicrobial and haemolytic activity of an amphipathic cyclic heptapeptide. European Journal of Medicinal Chemistry, 2015, 102, 574-581.	5.5	14
83	Analytic laboratory performance of a point of care urine culture kit for diagnosis and antibiotic susceptibility testing. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2111-2119.	2.9	11
84	European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. Clinical Microbiology and Infection, 2015, 21, 354-361.	6.0	44
85	Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study–authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 321-322.	3.0	3
86	Beta-Lactamase Producing Escherichia coli Isolates in Imported and Locally Produced Chicken Meat from Ghana. PLoS ONE, 2015, 10, e0139706.	2.5	31
87	Novel Method To Identify the Optimal Antimicrobial Peptide in a Combination Matrix, Using Anoplin as an Example. Antimicrobial Agents and Chemotherapy, 2014, 58, 1063-1070.	3.2	20
88	Antibacterial use in the Faroe Islands, Iceland, and Denmark 1999â€“2011. Scandinavian Journal of Infectious Diseases, 2014, 46, 502-507.	1.5	5
89	Antibiotic Selection of Escherichia coli Sequence Type 131 in a Mouse Intestinal Colonization Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 6139-6144.	3.2	24
90	Rapid Whole-Genome Sequencing for Detection and Characterization of Microorganisms Directly from Clinical Samples. Journal of Clinical Microbiology, 2014, 52, 139-146.	3.9	424

#	Article	IF	Citations
91	Tailoring Cytotoxicity of Antimicrobial Peptidomimetics with High Activity against Multidrug-Resistant Escherichia coli. Journal of Medicinal Chemistry, 2014, 57, 2864-2873.	6.4	44
92	Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 769-772.	3.0	57
93	Role of Urinary Cathelicidin LL-37 and Human Î²-Defensin 1 in Uncomplicated Escherichia coli Urinary Tract Infections. Infection and Immunity, 2014, 82, 1572-1578.	2.2	70
94	Faecal Escherichia coli from patients with E. coli urinary tract infection and healthy controls who have never had a urinary tract infection. Journal of Medical Microbiology, 2014, 63, 582-589.	1.8	86
95	Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. Journal of Antimicrobial Chemotherapy, 2014, 69, 2841-2847.	3.0	57
96	Selection of unique Escherichia coli clones by random amplified polymorphic DNA (RAPD): Evaluation by whole genome sequencing. Journal of Microbiological Methods, 2014, 103, 101-103.	1.6	20
97	Antibiotic Exposure in a Low-Income Country: Screening Urine Samples for Presence of Antibiotics and Antibiotic Resistance in Coagulase Negative Staphylococcal Contaminants. PLoS ONE, 2014, 9, e113055.	2.5	32
98	Microbial status and product labelling of 58 original tattoo inks. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 73-80.	2.4	51
99	Synthetic analogs of anoplin show improved antimicrobial activities. Journal of Peptide Science, 2013, 19, 669-675.	1.4	34
100	Penicillin resistance and serotype distribution of Streptococcus pneumoniaein Ghanaian children less than six years of age. BMC Infectious Diseases, 2013, 13, 490.	2.9	33
101	Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. International Journal of Antimicrobial Agents, 2013, 42, 272-275.	2.5	34
102	Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted caseâ€“control and cohort analysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 1894-1900.	3.0	49
103	Escherichia coli clonal group A causing bacteraemia of urinary tract origin. Clinical Microbiology and Infection, 2013, 19, 656-661.	6.0	17
104	Unusual pathogenic B1 genotype (yjaA/TspE4.C2) detected among Escherichia coli from pig, chicken broiler meat and human extraintestinal infection. Journal of Medical Microbiology, 2013, 62, 1259-1262.	1.8	2
105	Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. Journal of Antimicrobial Chemotherapy, 2012, 67, 2438-2444.	3.0	46
106	Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. Journal of Antimicrobial Chemotherapy, 2012, 67, 1325-1332.	3.0	44
107	Virulence factors and phylogenetic grouping of Escherichia coli isolates from patients with bacteraemia of urinary tract origin relate to sex and hospital- vs. community-acquired origin. International Journal of Medical Microbiology, 2012, 302, 129-134.	3.6	35
108	Extended-spectrum Î²-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: Prevalence, Î²-lactamase distribution, phylogroups, and co-resistance. Scandinavian Journal of Infectious Diseases, 2012, 44, 174-181.	1.5	43

#	Article	IF	Citations
109	Antimicrobial Activity of Peptidomimetics against Multidrug-Resistant Escherichia coli: A Comparative Study of Different Backbones. Journal of Medicinal Chemistry, 2012, 55, 7253-7261.	6.4	71
110	Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 268-274.	5.8	81
111	Is Escherichia coli urinary tract infection a zoonosis? Proof of direct link with production animals and meat. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1121-1129.	2.9	63
112	Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries. Scandinavian Journal of Infectious Diseases, 2011, 43, 707-713.	1.5	2
113	Emergence of extended-spectrum Î²-lactamase (ESBL)-producing Klebsiella pneumoniae in Danish hospitals; this is in part explained by spread of two CTX-M-15 clones with multilocus sequence types 15 and 16 in Zealand. International Journal of Antimicrobial Agents, 2011, 38, 180-182.	2.5	28
114	Silver resistance: an alarming public health concern?. International Journal of Antimicrobial Agents, 2011, 38, 454-455.	2.5	13
115	Infectious endocarditis caused by Escherichia coli. Scandinavian Journal of Infectious Diseases, 2011, 43, 545-546.	1.5	17
116	Fluoroquinolone Resistance Mechanisms in Urinary Tract PathogenicEscherichia coliIsolated During Rapidly Increasing Fluoroquinolone Consumption in a Low-Use Country. Microbial Drug Resistance, 2011, 17, 395-406.	2.0	19
117	Microarray-based detection of extended virulence and antimicrobial resistance gene profiles in phylogroup B2 Escherichia coli of human, meat and animal origin. Journal of Medical Microbiology, 2011, 60, 1502-1511.	1.8	51
118	Genome-Wide Identification ofStreptococcus pneumoniaeGenes Essential for Bacterial Replication during Experimental Meningitis. Infection and Immunity, 2011, 79, 288-297.	2.2	62
119	Intra- and Extracellular Activities of Dicloxacillin and Linezolid against a ClinicalStaphylococcus aureusStrain with a Small-Colony-Variant Phenotype in anIn VitroModel of THP-1 Macrophages and anIn VivoMouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1443-1452.	3.2	19
120	Persisting clones of Escherichia coli isolates from recurrent urinary tract infection in men and women. Journal of Medical Microbiology, 2011, 60, 550-554.	1.8	29
121	Characteristics ofEscherichia colicausing persistence or relapse of urinary tract infections: Phylogenetic groups, virulence factors and biofilm formation. Virulence, 2011, 2, 528-537.	4.4	102
122	Recurrent bacteraemia: A 10-year regional population-based study of clinical and microbiological risk factors. Journal of Infection, 2010, 60, 191-199.	3.3	23
123	Broiler chickens, broiler chicken meat, pigs and pork as sources of ExPEC related virulence genes and resistance in Escherichia coli isolates from community-dwelling humans and UTI patientsâ˜†. International Journal of Food Microbiology, 2010, 142, 264-272.	4.7	124
124	Antimicrobial, Hemolytic, and Cytotoxic Activities of Î²â€Peptoidâ€“Peptide Hybrid Oligomers: Improved Properties Compared to Natural AMPs. ChemBioChem, 2010, 11, 1356-1360.	2.6	80
125	Development of Azole Resistance in Aspergillus fumigatus during Azole Therapy Associated with Change in Virulence. PLoS ONE, 2010, 5, e10080.	2.5	143
126	Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 942-945.	3.0	29

#	Article	IF	Citations
127	Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. Journal of Antimicrobial Chemotherapy, 2010, 65, 981-985.	3.0	27
128	Virulence of Escherichia coli B2 Isolates from Meat and Animals in a Murine Model of Ascending Urinary Tract Infection (UTI): Evidence that UTI Is a Zoonosis. Journal of Clinical Microbiology, 2010, 48, 2978-2980.	3.9	25
129	Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 1720-1724.	3.0	41
130	Escherichia coliIsolates from Broiler Chicken Meat, Broiler Chickens, Pork, and Pigs Share Phylogroups and Antimicrobial Resistance with Community-Dwelling Humans and Patients with Urinary Tract Infection. Foodborne Pathogens and Disease, 2010, 7, 537-547.	1.8	116
131	Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. Journal of Antimicrobial Chemotherapy, 2010, 65, 1286-1291.	3.0	49
132	Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. Journal of Antimicrobial Chemotherapy, 2010, 65, 962-973.	3.0	24
133	Intra- and Extracellular Activities of Dicloxacillin against Staphylococcus aureus In Vivo and In Vitro. Antimicrobial Agents and Chemotherapy, 2010, 54, 2391-2400.	3.2	21
134	A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane. Antimicrobial Agents and Chemotherapy, 2010, 54, 3341-3346.	3.2	103
135	Detection of Clonal Group A Escherichia coli Isolates from Broiler Chickens, Broiler Chicken Meat, Community-Dwelling Humans, and Urinary Tract Infection (UTI) Patients and Their Virulence in a Mouse UTI Model. Applied and Environmental Microbiology, 2010, 76, 8281-8284.	3.1	30
136	Characterization and transfer studies of macrolide resistance genes in Streptococcus pneumoniae from Denmark. Scandinavian Journal of Infectious Diseases, 2010, 42, 586-593.	1.5	6
137	Plectasin Shows Intracellular Activity against Staphylococcus aureus in Human THP-1 Monocytes and in a Mouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 4801-4808.	3.2	59
138	High Cerebrospinal Fluid (CSF) Penetration and Potent Bactericidal Activity in CSF of NZ2114, a Novel Plectasin Variant, during Experimental Pneumococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2009, 53, 1581-1585.	3.2	37
139	Consequences of increased antibacterial consumption and change in pattern of antibacterial use in Danish hospitals. Journal of Antimicrobial Chemotherapy, 2009, 63, 812-815.	3.0	17
140	Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness. PLoS Pathogens, 2009, 5, e1000541.	4.7	291
141	Intracellular Activity of Antibiotics against Staphylococcus aureus in a Mouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 1874-1883.	3.2	66
142	Influence of Antidrug Antibodies on Plectasin Efficacy and Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2009, 53, 4794-4800.	3.2	20
143	Routes, dynamics, and correlates of cochlear inflammation in terminal and recovering experimental meningitis. Laryngoscope, 2009, 119, 1560-1570.	2.0	20
144	Neonatal colonization withStaphylococcus aureusis not associated with development of atopic dermatitis. British Journal of Dermatology, 2009, 160, 1286-1291.	1.5	24

#	Article	IF	Citations
145	Fallaxin analogues with improved antibacterial activity. Advances in Experimental Medicine and Biology, 2009, 611, 531-532.	1.6	0
146	The prevalence of ESBLâ€producing E. coli andKlebsiella strains in the Copenhagen area of Denmark. Apmis, 2008, 116, 118-124.	2.0	27
147	The Effect of S. Pneumoniae Bacteremia on Cerebral Blood Flow Autoregulation in Rats. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 126-134.	4.3	19
148	Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clinical Microbiology and Infection, 2008, 14, 74-81.	6.0	56
149	Prevalence of Quinolone Resistance Mechanisms and Associations to Minimum Inhibitory Concentrations in Quinolone-ResistantEscherichia coliIsolated from Humans and Swine in Denmark. Microbial Drug Resistance, 2008, 14, 163-169.	2.0	70
150	Prevalence of sulphonamide resistance and class 1 integron genes in Escherichia coli isolates obtained from broilers, broiler meat, healthy humans and urinary infections in Denmark. International Journal of Antimicrobial Agents, 2008, 32, 367-369.	2.5	33
151	Experimental guinea pig model of dermatophytosis: a simple and useful tool for the evaluation of new diagnostics and antifungals. Medical Mycology, 2008, 46, 303-313.	0.7	39
152	Characterisation, dissemination and persistence of gentamicin resistant Escherichia coli from a Danish university hospital to the waste water environment. Environment International, 2008, 34, 108-115.	10.0	59
153	Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents. Antimicrobial Agents and Chemotherapy, 2008, 52, 3229-3236.	3.2	126
154	Antimicrobial Activities of Twenty Lysine-Peptoid Hybrids against Clinically Relevant Bacteria and Fungi. Chemotherapy, 2008, 54, 152-156.	1.6	54
155	Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals. Journal of Antimicrobial Chemotherapy, 2008, 62, 1203-1206.	3.0	61
156	Vancomycin-resistant Enterococcus faecalis isolates from a Danish patient and two healthy human volunteers are possibly related to isolates from imported turkey meat. Journal of Antimicrobial Chemotherapy, 2008, 62, 844-845.	3.0	30
157	Natural transfer of sulphonamide and ampicillin resistance between Escherichia coli residing in the human intestine. Journal of Antimicrobial Chemotherapy, 2008, 63, 80-86.	3.0	74
158	Impact of Bacteremia on the Pathogenesis of Experimental Pneumococcal Meningitis. Journal of Infectious Diseases, 2008, 197, 235-244.	4.0	34
159	Laboratory-based Survey of Dermatophyte Infections in Denmark over a 10-year Period. Acta Dermato-Venereologica, 2008, 88, 614-616.	1.3	33
160	First detection of plasmid-mediated quinolone resistance (qnrA and qnrS) in Escherichia coli strains isolated from humans in Scandinavia. Journal of Antimicrobial Chemotherapy, 2007, 59, 804-805.	3.0	33
161	Changing Epidemiology of Pediatric Staphylococcus aureus Bacteremia in Denmark From 1971 Through 2000. Pediatric Infectious Disease Journal, 2007, 26, 398-405.	2.0	59
162	Association between antimicrobial resistance and virulence genes in Escherichia coli obtained from blood and faeces. Scandinavian Journal of Infectious Diseases, 2007, 39, 724-727.	1.5	15

#	Article	IF	Citations
163	P2072 Bactericidal effect of Ltx peptides against Staphylococcus aureus in vitro and in murine skin infection model. International Journal of Antimicrobial Agents, 2007, 29, S598.	2.5	0
164	P1398 The impact of empiric antimicrobial treatment and the clinical microbiological guidance in sepsis. International Journal of Antimicrobial Agents, 2007, 29, S389.	2.5	0
165	P1374 Comparison of oral dosing regimes for pivampicillin by Monte Carlo PK/PD simulation. International Journal of Antimicrobial Agents, 2007, 29, S381.	2.5	0
166	P1012 First cases of infection with Escherichia coli containing plasmid-mediatedfiuoroquinolone resistance (qnrA and qnrS) in Scandinavia. International Journal of Antimicrobial Agents, 2007, 29, S270.	2.5	0
167	Comment on: withdrawal of growth-promoting antibiotics in Europe and its effects in relation to human health. International Journal of Antimicrobial Agents, 2007, 30, 466-468.	2.5	37
168	Cerebral blood flow autoregulation in early experimental S. pneumoniae meningitis. Journal of Applied Physiology, 2007, 102, 72-78.	2.5	21
169	Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clinical Microbiology and Infection, 2007, 13, 257-263.	6.0	129
170	Gentamicin susceptibility in Escherichia coli related to the genetic background: problems with breakpoints. Clinical Microbiology and Infection, 2007, 13, 830-832.	6.0	20
171	Structureâ€“activity study of the antibacterial peptide fallaxin. Protein Science, 2007, 16, 1969-1976.	7.6	38
172	Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniaemeningitis. BMC Infectious Diseases, 2006, 6, 78.	2.9	14
173	Detection of sul1, sul2 and sul3 in sulphonamide resistant Escherichia coli isolates obtained from healthy humans, pork and pigs in Denmark. International Journal of Food Microbiology, 2006, 106, 235-237.	4.7	94
174	Hearing loss and cochlear damage in experimental pneumococcal meningitis, with special reference to the role of neutrophil granulocytes. Neurobiology of Disease, 2006, 23, 300-311.	4.4	23
175	Food Safety Revisited. Journal of Infectious Diseases, 2006, 194, 1191-1193.	4.0	4
176	Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 2006, 58, 1291-1294.	3.0	4
177	Pulsed-Field Gel Electrophoresis Typing of Escherichia coli Strains from Samples Collected before and after Pivmecillinam or Placebo Treatment of Uncomplicated Community-Acquired Urinary Tract Infection in Women. Journal of Clinical Microbiology, 2006, 44, 1776-1781.	3.9	71
178	In Vivo Transfer of the vanA Resistance Gene from an Enterococcus faecium Isolate of Animal Origin to an E. faecium Isolate of Human Origin in the Intestines of Human Volunteers. Antimicrobial Agents and Chemotherapy, 2006, 50, 596-599.	3.2	213
179	Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature, 2005, 437, 975-980.	27.8	557
180	Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. Journal of Neuroimmunology, 2005, 166, 126-131.	2.3	35

#	Article	IF	Citations
181	Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections. Antimicrobial Agents and Chemotherapy, 2005, 49, 2343-2351.	3.2	132
182	The More Antibacterial Trade Names, The More Consumption of Antibacterials: A European Study. Clinical Infectious Diseases, 2005, 41, 114-117.	5.8	39
183	High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. J Antimicrob Chemother 2005; 55: 748â€“57]. Journal of Antimicrobial Chemotherapy, 2005, 56, 433-434.	3.0	2
184	Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice. Journal of Antimicrobial Chemotherapy, 2005, 55, 383-386.	3.0	53
185	Evaluation of cefoxitin 5 and 10â€‰Î¼g discs for the detection of methicillin resistance in staphylococci. Journal of Antimicrobial Chemotherapy, 2005, 55, 157-161.	3.0	40
186	Fighting MRSA in hospitals: time to restrict the broad use of specific antimicrobial classes?. Journal of Hospital Infection, 2005, 61, 267-268.	2.9	9
187	Susceptibility testing of urinary isolates of Escherichia coli to mecillinam using NCCLS methodology. International Journal of Antimicrobial Agents, 2005, 25, 198-204.	2.5	1
188	Attenuation of the Bacterial Load in Blood by Pretreatment with Granulocyte-Colony-Stimulating Factor Protects Rats from Fatal Outcome and Brain Damage during Streptococcus pneumoniae Meningitis. Infection and Immunity, 2004, 72, 4647-4653.	2.2	34
189	Polymorphic Mutation Frequencies in Escherichia coli: Emergence of Weak Mutators in Clinical Isolates. Journal of Bacteriology, 2004, 186, 5538-5542.	2.2	74
190	A vancomycin-resistant Enterococcus faecium isolate from a Danish healthy volunteer, detected 7 years after the ban of avoparcin, is possibly related to pig isolates. Journal of Antimicrobial Chemotherapy, 2004, 53, 547-549.	3.0	33
191	Microbial Threat - the Copenhagen Recommendations Initiative of the EU. Zoonoses and Public Health, 2004, 51, 400-402.	1.4	14
192	Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clinical Microbiology and Infection, 2004, 10, 54-61.	6.0	21
193	Only percentage within species; neither incidence, nor prevalence: demographic information and representative surveillance data are urgently needed to estimate the burden of antimicrobial resistance. International Journal of Antimicrobial Agents, 2004, 24, 622-623.	2.5	4
194	Nasopharyngeal pathogens in children with acute otitis media in a low-antibiotic use country. International Journal of Pediatric Otorhinolaryngology, 2004, 68, 1149-1155.	1.0	11
195	Conjugal transfer of aminoglycoside and macrolide resistance between Enterococcus faecium isolates in the intestine of streptomycin-treated mice. FEMS Microbiology Letters, 2004, 235, 385-391.	1.8	24
196	Tetracycline and Macrolide Co-Resistance in <I>Streptococcus pyogenes:</I> Co-Selection As a Reason for Increase in Macrolide-Resistant <I>S. pyogenes?</I>. Microbial Drug Resistance, 2004, 10, 231-238.	2.0	4
197	Evaluation of different disk diffusion/media combinations for detection of methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci. Apmis, 2003, 111, 905-914.	2.0	11
198	Tentative interpretative zone diameters for fusidic acid NeosensitabsÂ® on Mueller Hinton agar and three blood containing media. International Journal of Antimicrobial Agents, 2003, 22, 502-507.	2.5	6

#	Article	IF	Citations
199	Effects of Sulfamethizole and Amdinocillin against Escherichia coli Strains (with Various) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Chemotherapy, 2003, 47, 1002-1009.	3.2	34
200	Evaluation of fusidic acid in therapy of experimental Staphylococcus aureus meningitis. Journal of Antimicrobial Chemotherapy, 2003, 51, 1301-1305.	3.0	12
201	Evaluation of a cefoxitin 30 Âg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2003, 52, 204-207.	3.0	100
202	Selection of Resistant Streptococcus pneumoniae during Penicillin Treatment In Vitro and in Three Animal Models. Antimicrobial Agents and Chemotherapy, 2003, 47, 2499-2506.	3.2	33
203	Detection of tet(M), tet(O) and tet(S) in tetracycline/minocycline-resistant Streptococcus pyogenes bacteraemia isolates. Journal of Antimicrobial Chemotherapy, 2003, 53, 118-119.	3.0	8
204	Treatment and Outcome of Staphylococcus aureus Bacteremia. Archives of Internal Medicine, 2002, 162, 25.	3.8	230
205	Validation of FLEXICULTâ„¢ SSI-Urinary Kit For Use in the Primary Health Care Setting. Scandinavian Journal of Infectious Diseases, 2002, 34, 430-435.	1.5	24
206	Beta-hemolytic Streptococcal Bacteremia: A Review of 241 Cases. Scandinavian Journal of Infectious Diseases, 2002, 34, 483-486.	1.5	12
207	Susceptibility of Danish Escherichia coli strains isolated from urinary tract infections and bacteraemia, and distribution of sul genes conferring sulphonamide resistance. Journal of Antimicrobial Chemotherapy, 2002, 50, 513-516.	3.0	197
208	How predictive is PK/PD for antibacterial agents?. International Journal of Antimicrobial Agents, 2002, 19, 333-339.	2.5	104
209	Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. International Journal of Antimicrobial Agents, 2002, 19, 546-553.	2.5	89
210	Differences in Antibiotic Prescribing Patterns Between General Practitioners in Scandinavia: A Questionnaire Study. Scandinavian Journal of Infectious Diseases, 2002, 34, 602-609.	1.5	22
211	In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model. Infection, 2002, 30, 286-291.	4.7	147
212	In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime. Apmis, 2002, 110, 559-564.	2.0	4
213	Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility testing using NCCLS methodology for fusidic acid. Diagnostic Microbiology and Infectious Disease, 2001, 40, 111-116.	1.8	37
214	Control of resistance to sulphonamides. Lancet, The, 2001, 358, 761-762.	13.7	1
215	A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age. BJU International, 2001, 84, 827-834.	2.5	52
216	In vitro antimicrobial susceptibility of Aerococcus urinae to 14 antibiotics, and time-kill curves for penicillin, gentamicin and vancomycin. Journal of Antimicrobial Chemotherapy, 2001, 48, 653-658.	3.0	57

#	Article	IF	Citations
217	In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia. Antimicrobial Agents and Chemotherapy, 2001, 45, 1860-1867.	3.2	122
218	Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models. Antimicrobial Agents and Chemotherapy, 2001, 45, 1078-1085.	3.2	34
219	Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. Journal of Antimicrobial Chemotherapy, 2001, 47, 521-526.	3.0	37
220	Transient Intestinal Carriage after Ingestion of Antibiotic-ResistantEnterococcus faeciumfrom Chicken and Pork. New England Journal of Medicine, 2001, 345, 1161-1166.	27.0	152
221	Antimicrobial-Drug Use and Methicillin-Resistant Staphylococcus aureus. Emerging Infectious Diseases, 2001, 7, 161-163.	4.3	29
222	Treatment with a monoclonal antibody to IL-8 attenuates the pleocytosis in experimental pneumococcal meningitis in rabbits when given intravenously, but not intracisternally. Clinical and Experimental Immunology, 2000, 122, 207-211.	2.6	32
223	Inhibition of Leukocyte Entry into the Brain by the Selectin Blocker Fucoidin Decreases Interleukin-1 (IL-1) Levels but Increases IL-8 Levels in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. Infection and Immunity, 2000, 68, 3153-3157.	2.2	58
224	Development of a Long-Term Ascending Urinary Tract Infection Mouse Model for Antibiotic Treatment Studies. Antimicrobial Agents and Chemotherapy, 2000, 44, 156-163.	3.2	119
225	Pharmacodynamics of Glycopeptides in the Mouse Peritonitis Model of Streptococcus pneumoniae or Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2000, 44, 1247-1254.	3.2	98
226	In vitro study of the susceptibility of Escherichia coli to mecillinam. Journal of Antimicrobial Chemotherapy, 2000, 45, 920-921.	3.0	3
227	Evaluation of calibrated 1 and 10 mul loops and dipslide as compared to pipettes for detection of low count bacteriuria in vitroNote. Apmis, 2000, 108, 525-530.	2.0	9
228	Clinical Features of Staphylococcus aureus Endocarditis. Archives of Internal Medicine, 1999, 159, 462.	3.8	142
229	Presence ofermgene classes in Gram-positive bacteria of animal and human origin in Denmark. FEMS Microbiology Letters, 1999, 170, 151-158.	1.8	199
230	Detection of clinical vancomycinâ€resistant enterococci in Denmark by multiplex PCR and sandwich hybridization. Apmis, 1999, 107, 404-412.	2.0	16
231	Risk Factors for Hospital-Acquired Staphylococcus aureus Bacteremia. Archives of Internal Medicine, 1999, 159, 1437.	3.8	137
232	Pharmacodynamics of penicillin are unaffected by bacterial growth phases of Streptococcus pneumoniae in the mouse peritonitis model. Journal of Antimicrobial Chemotherapy, 1998, 41, 451-459.	3.0	17
233	Bacteremic Staphylococcus aureus Spondylitis. Archives of Internal Medicine, 1998, 158, 509.	3.8	139
234	Problems with Antibiotic Resistance in Spain and Their Relation to Antibiotic Use in Humans Elsewhere. Clinical Infectious Diseases, 1997, 25, 939-941.	5.8	17

#	Article	IF	Citations
235	Antimicrobial resistance in Salmonella enterica subsp. enterica serovar typhimurium from humans and production animals. Journal of Antimicrobial Chemotherapy, 1997, 40, 67-75.	3.0	55
236	Experience with Once Daily Dosing of Gentamicin: Considerations Regarding Dosing and Monitoring. Chemotherapy, 1997, 43, 442-450.	1.6	19
237	A Study of 47 Bacteremic Staphylococcus aureus Endocarditis Cases: 23 with Native Valves Treated Surgically and 24 with Prosthetic Valves. Scandinavian Cardiovascular Journal, 1997, 31, 305-309.	1.2	22
238	Neurologic Manifestations in Staphylococcus aureus Endocarditis: A Review of 260 Bacteremic Cases in Nondrug Addicts. American Journal of Medicine, 1997, 102, 379-386.	1.5	139
239	Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrobial Agents and Chemotherapy, 1997, 41, 1910-1915.	3.2	52
240	Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model. Journal of Antimicrobial Chemotherapy, 1997, 40, 679-686.	3.0	16
241	Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time. Antimicrobial Agents and Chemotherapy, 1997, 41, 2634-2639.	3.2	52
242	Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980â€“1990. Journal of Infection, 1997, 34, 113-118.	3.3	167
243	Author's concluding statement. Infection, 1996, 24, 272-272.	4.7	0
244	Clinical manifestations and molecular epidemiology ofVibrio vulnificus infections in Denmark. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 227-232.	2.9	141
245	In vitroactivity of six macrolides, clindamycin and tetracycline onStreptococcus pneumoniaewith different penicillin susceptibilities. Apmis, 1996, 104, 227-233.	2.0	9
246	Detection of penicillin resistance inStreptococcus pneumoniaeby diffusion tests. Apmis, 1996, 104, 549-556.	2.0	0
247	Aminoglycoside resistance mechanisms in Enterobacteriaceae and Pseudomonas spp. from two Danish hospitals: correlation with type of aminoglycoside used. Apmis, 1996, 104, 763-768.	2.0	13
248	Aminoglycoside resistance among Danish blood culture isolates of coagulase-negative staphylococci. Apmis, 1996, 104, 873-880.	2.0	9
249	Retrograde contamination and practical handling of urine-meters: a comparison of three systems for the measurement of hourly diuresis in an experimental bladder-drainage model and in clinical use. British Journal of Urology, 1996, 78, 187-191.	0.1	7
250	Staphylococcus aureus Bacteremia: a 14-year Nationwide Study in Hematological Patients with Malignant Disease or Agranulocytosis. Scandinavian Journal of Infectious Diseases, 1995, 27, 563-568.	1.5	20
251	Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection, 1995, 23, 107-112.	4.7	50
252	Staphylococcus aureus Endocarditis in Danish Intravenous Drug Users: High Proportion of Left-Sided Endocarditis. Scandinavian Journal of Infectious Diseases, 1995, 27, 483-487.	1.5	21

#	Article	IF	Citations
253	Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrobial Agents and Chemotherapy, 1995, 39, 1253-1258.	3.2	71
254	Collagen with gentamicin for prophylaxis of postoperative infection:Staphylococcus aureusosteomyelitis studied in rabbits. Acta Orthopaedica, 1995, 66, 69-72.	1.4	35
255	Effect of treatment with methicillin and gentamicin in a new experimental mouse model of foreign body infection. Antimicrobial Agents and Chemotherapy, 1994, 38, 2047-2053.	3.2	17
256	Attachment of staphylococci to different plastic tubes in vitro. Journal of Medical Microbiology, 1994, 40, 37-42.	1.8	20
257	Infections with the Unusual Human Pathogens Agrobacterium Species and Ochrobactrum anthropi. Clinical Infectious Diseases, 1994, 18, 914-920.	5.8	143
258	The antibacterial activity of a siderophore. Apmis, 1994, 102, 219-226.	2.0	8
259	Epidemiology ofStaphylococcus aureusBacteremia in Denmark. Journal of Chemotherapy, 1994, 6, 219-225.	1.5	16
260	Catheter-related Staphylococcus aureus infections. Journal of Hospital Infection, 1993, 23, 123-131.	2.9	21
261	Ceftriaxone versus latamoxef in febrile neutropenic patients: Empirical monotherapy in patients with solid tumours. European Journal of Cancer, 1993, 29, 1274-1279.	2.8	5
262	Hyponatremia and Adrenocortical Function in Patients with Severe Bacterial Infections. Scandinavian Journal of Infectious Diseases, 1993, 25, 101-105.	1.5	8
263	Experimental foreign body infection in mice. Journal of Antimicrobial Chemotherapy, 1993, 31, 103-111.	3.0	36
264	The mouse peritonitis model: present and future use. Journal of Antimicrobial Chemotherapy, 1993, 31, 55-60.	3.0	45
265	Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Archives of Internal Medicine, 1993, 153, 1902-1908.	3.8	39
266	Hyponatremia and Adrenocortical Function in Patients with Severe Bacterial Infections. Scandinavian Journal of Infectious Diseases, 1993, 25, 101-105.	1.5	1
267	Treatment of pleural empyema secondary to pneumonia: thoracocentesis regimen versus tube drainage.. Thorax, 1992, 47, 821-824.	5.6	70
268	Nosocomial Pneumonia in an Intensive Care Unit in a Danish University Hospital: Incidence, Mortality and Etiology. Scandinavian Journal of Infectious Diseases, 1992, 24, 65-70.	1.5	20
269	Killing curve activity of ciprofloxacin is comparable to synergistic effect of Î²â€lactamâ€tobramycin combinations against Haemophilus species endocarditis strains. Apmis, 1992, 100, 856-860.	2.0	2
270	Synovectomy for septic arthritis: Early versus late synovectomy studied in the rabbit knee. Acta Orthopaedica, 1991, 62, 315-318.	1.4	15

#	Article	IF	Citations
271	The antibacterial activity of a siderophore. Apmis, 1991, 99, 879-886.	2.0	8
272	Mechanism of aminoglycoside resistance in Danish Staphylococcus aureus strains during the years 1979â€“1987. Apmis, 1991, 99, 537-540.	2.0	4
273	Bactericidal effect of penicillin, ampicillin, and amoxicillin alone and in combination with tobramycin against Enterococcus faecalis as determined by kill-kinetic studies. Infection, 1991, 19, 170-173.	4.7	14
274	Antibiotic Prophylaxis in Non-Cardiac Thoracic Surgery: A Double-blind Study of Penicillin vs. Cefuroxime. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1991, 25, 73-76.	0.2	10
275	Antibiotic treatment insufficient for established septic arthritis Staphylococcus aureus experiments in rabbits. Acta Orthopaedica, 1989, 60, 113-115.	1.4	37
276	Resistance to dicloxacillin, methicillin and oxacillin in methicillinâ€susceptible and methicillinâ€resistant Staphylococcus aureus detected by dilution and diffusion methods. Apmis, 1989, 97, 715-722.	2.0	11
277	In vitro activity of dicloxacillin against methicillinâ€susceptible and methicillinâ€resistant Staphylococcusâ€aureus. Apmis, 1989, 97, 207-211.	2.0	4
278	The antibacterial activity of a siderophore. Apmis, 1989, 97, 419-424.	2.0	12
279	Staphylococcus aureus Bacteraemia in Children below the Age of One Year.. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 56-61.	1.5	12
280	In vitro antibacterial activities of eleven antibiotics against S. faecalis. Apmis, 1988, 96, 584-588.	2.0	4
281	Synergy between a nonâ€neuroleptic thioxanthene stereoâ€isomer and penicillin in vivo. Apmis, 1988, 96, 1079-1084.	2.0	14
282	Antibiotic penetration into the infected knee: A rabbit experiment. Acta Orthopaedica, 1987, 58, 256-259.	1.4	20
283	Rabbit model of septic arthritis. Acta Orthopaedica, 1987, 58, 14-19.	1.4	55
284	Antibiotic Treatment of Staphylococcus aureus Endocarditis. Acta Medica Scandinavica, 1987, 222, 175-182.	0.0	14
285	Staphylococcus aureus Bacteremia in Patients with Hematological Malignancies and/or Agranulocytosis. Acta Medica Scandinavica, 1987, 222, 465-470.	0.0	21
286	THE PNEUMOCOCCUS AND THE MOUSEâ€PROTECTION TEST: CORRELATION OF IN VITRO AND IN VIVO ACTIVITY FOR BETAâ€LACTAM ANTIBIOTICS, VANCOMYCIN, ERYTHROMYCIN AND GENTAMICIN. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology, 1987, 95B, 159-165.	0.1	10
287	Experimental Infection with Streptococcus pneumoniae in Mice: Correlation of in Vitro Activity and Pharmacokinetic Parameters with in Vivo Effect for 14 Cephalosporins. Journal of Infectious Diseases, 1986, 154, 511-517.	4.0	92
288	Relationship between penicillinase production and the in-vitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase activity. Journal of Antimicrobial Chemotherapy, 1986, 18, 27-33.	3.0	15

#	Article	IF	Citations
289	Antibiotic prophylaxis in vascular reconstructive surgery: a double-blind placebo-controlled study. Journal of Antimicrobial Chemotherapy, 1986, 17, 105-113.	3.0	38
290	In-vitro activity of methiciilin against clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 1985, 15, 173-180.	3.0	11
291	Serum Concentrations of TobramycinÂ® After Intraarticular Administration: An Experimental Study in the Rabbit. Acta Orthopaedica, 1983, 54, 446-448.	1.4	1
292	The Pneumococcus and the Mouse Protection Test: Importance of the Lag Phase in vivo. Chemotherapy, 1983, 29, 128-134.	1.6	23
293	Antibiotic Prophylaxis in Pulmonary Surgery. Annals of Surgery, 1982, 195, 444-450.	4.2	35
294	Cinoxacin in urinary tract infections theoretical and practical considerations. Urology, 1981, 17, 496-499.	1.0	6
295	Prophylactic Antibiotics in Transurethral Prostatectomy. Journal of Urology, 1981, 126, 60-62.	0.4	90
296	Nitroimidazoles in the canine prostate, vagina, and urethra. Prostate, 1981, 2, 71-78.	2.3	6
297	Rosoxacin distribution in kidney and prostate: experimental studies in dogs. Urological Research, 1980, 8, 113-116.	1.5	4
298	Mezlocillin Pharmacokinetics After Single Intravenous Doses to Patients with Varying Degrees of Renal Function. Antimicrobial Agents and Chemotherapy, 1980, 17, 599-607.	3.2	21
299	Mecillinam in urinary tract infections and in septicaemia. Infection, 1979, 7, 35-37.	4.7	2